AC 7739

Drug Profile

AC 7739

Latest Information Update: 28 Oct 2004

Price : $50

At a glance

  • Originator Ajinomoto
  • Class Antineoplastics; Stilbenes
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Oct 2004 Discontinued - Preclinical for Cancer in Japan (unspecified route)
  • 08 Feb 2001 No-Development-Reported for Cancer in Japan (Unknown route)
  • 31 Mar 1998 Preclinical development for Cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top